# Return of Individual Research Results from Genomic Studies By the end of this guide, you will be able to design a return-of-results plan for a genomic study, triage findings into return, hold, and do-not-return categories, build consent and disclosure materials participants actually understand, and set up the urgent-result and raw-data pathways that first-time implementers most often miss. Before you start, have on hand your study protocol and consent template, a list of every data type your assay generates, your ethics committee or institutional review board contact, a named genetics professional or consultation service, and a budget line for confirmation testing and counseling. Return of individual research results from genomic studies means giving each participant information derived from their own genome or biological samples rather than only cohort-level summaries. The practice has moved from a contested idea to an accepted expectation in observational cohorts and biobanks, and it is now treated as part of responsible conduct of research and modern [research ethics](/blog/guides/research-ethics-fundamentals-a-practical-guide-for-early-career-scientists) rather than an optional courtesy [1]. This guide walks through the full workflow with a triage algorithm, worked calculations, a decision table, and the documented mistakes to avoid. ## What Counts as an Individual Research Result Individual results differ from aggregate results. Aggregate results describe the study population as a whole. Individual results describe one participant, such as that person's own variant status. Three categories matter for planning: 1. **Primary results** are findings directly related to the study question. 2. **Secondary findings** are findings unrelated to the study aim that may still matter clinically. The literature also calls these incidental findings. The 100,000 Genomes Project used the term additional findings for a defined list of variants associated with cancer susceptibility and familial hypercholesterolemia that participants could elect to receive [2]. 3. **Raw data** are unprocessed or minimally processed sequence files that participants may request even when no interpreted result is offered [3]. A result becomes a candidate for return when it is clinically actionable, meaning a preventable or treatable action exists, and when it is analytically valid and reliable. This triple filter of actionability, validity, and reliability is the emerging consensus among researchers deciding what multi-omics data, meaning combined measurements across genomes and other molecular layers, can support individual disclosure [4]. Newer result types stretch the filter. Polygenic risk scores estimate disease risk from many variants at once and behave probabilistically rather than deterministically. Somatic mosaicism describes genetic changes present in only some cells. Pharmacogenomic variants predict drug response. All three are now on the return-of-results agenda for cohort studies, each with its own evidence requirements [1]. ## Why the Norm Has Shifted Toward Returning Results The shift rests on three arguments. First, reciprocity, the idea that participants deserve something back for their contribution. In facilitated engagement discussions with a low grade glioma genomic research community that included patients, care partners, clinicians, and researchers, participants expressed strong support for receiving both individual and aggregate results, framing return as recognition for their contribution [5]. Second, the right to know. In a continental survey of 110 researchers, science policy makers, and research ethics committee members working in African genomics, respondents held that clinically actionable results should be returned because participants have a right to know things about their health and because return recognizes their participation [6]. Third, established research ethics principles. A systematic review of 32 report-back studies published between 2016 and 2024 mapped return-of-results strategies onto autonomy, beneficence, nonmaleficence, and justice, and found that involving participants in developing reports improves comprehension, trust, and engagement with findings [7]. Standardized guidelines remain limited, which is why program-level planning matters [7]. Against this backdrop, a 2024 National Heart, Lung and Blood Institute workshop concluded that return of secondary genomic findings in observational cohort studies has evolved from a topic of debate to an accepted standard [1]. ## Step-by-Step: Return of Individual Research Results in Genomic Studies The eight steps below follow the sequence large programs actually use, from scoping decisions through disclosure and evaluation. ### Step 1. Decide What You Will Return ![Calculation showing 23 of 48 reviewed variants recommended for return, about 48 percent, and the staffing implication.](/article-images/illustrations/return-of-individual-research-results-genomic-studies-returnable-share.webp) List every result category your assay can generate, then apply the actionability, validity, and reliability filter [4]. A practical category list for a sequencing study looks like this: - Urgent clinical findings from research procedures - Pathogenic variants in preventable or treatable conditions - Pharmacogenomic variants with prescribing guidance - Carrier status for recessive conditions - Polygenic risk scores - Raw data - Aggregate results Expect a fraction, not all, of your findings to pass. At the Hospital for Sick Children, a consultation service called the Genome Board reviewed 67 submissions from researchers over four years. The most common request, 60 percent of submissions, was to assess variants for pathogenicity, clinical actionability, and returnability, and of 48 variants reviewed, 23 were recommended for clinical confirmation and return with genetic counseling [8]. Worked calculation: 23 / 48 = 0.479, so roughly 48 percent of variants reaching expert review in a pediatric research setting were judged returnable. Plan disclosure infrastructure for about half of reviewed findings, not all of them. For polygenic risk scores, be conservative. Parkinson disease illustrates the problem, since most disease-associated variants confer probabilistic risk rather than deterministic outcomes, which limits individual-level prediction and complicates disclosure [9]. Large genetic studies in Parkinson disease identified pathogenic variants in approximately 10 to 20 percent of patients, and even those results require careful framing to avoid overinterpretation [9]. ### Step 2. Build Consent and Communication Around the Plan Consent should name the result categories you will offer, state what you will not return, and record data sharing preferences. The Australian Reproductive Genetic Carrier Screening Project, Mackenzie's Mission, shows how much preferences vary. Of enrolled individuals, 76.5 percent gave broad consent, meaning permission for future unspecified research uses, while 23.5 percent, 4,288 people, chose to answer ten specific preference questions. Those who answered were most permissive about sharing with universities, 78.2 percent, and not-for-profit organizations, 78.0 percent, and least permissive about commercial organizations, 33.7 percent, and governments, 59.2 percent. Nearly 60 percent wanted notification every time their data was shared [10]. Build consent modules that capture this granularity instead of assuming broad consent covers every use. Structured question lists help participants consent meaningfully. A rigorously developed Question Prompt List for genomic testing and research in oncology contains 29 items across three sections covering the profiling test itself, the results, and the research study, and patients, carers, clinicians, and researchers judged it useful for informed consent [11]. Co-develop materials with the communities you study, because the report-back literature consistently finds that participant involvement in developing reports improves comprehension, trust, and engagement [7]. ### Step 3. Triage Findings Through Expert Review Encode your decision rules so every finding is handled the same way. The following logic mirrors published frameworks: ```python def triage_finding(finding): """Decision logic for return of individual research results in genomic studies, based on published frameworks.""" if finding.is_urgent_clinical: return "URGENT: contact the participant now and activate a clinical referral pathway" if not finding.confirmed_in_clinical_lab: return "HOLD: send for clinical confirmation before any disclosure" if finding.pathogenic and finding.condition_preventable_or_treatable: return "OFFER: disclose with genetic counseling" if finding.is_pharmacogenomic and finding.has_prescribing_guidance: return "OFFER: disclose with prescribing context" if finding.is_polygenic_risk_score: return "REVIEW: return only with ancestry-validated performance and support" return "DO NOT RETURN individually: keep for aggregate reporting" ``` Expected output for four example findings: ``` Finding 1 (incidental lung nodule seen on research imaging) -> URGENT: contact the participant now and activate a clinical referral pathway Finding 2 (pathogenic variant linked to a treatable condition, research grade) -> HOLD: send for clinical confirmation before any disclosure Finding 3 (pharmacogenomic variant with prescribing guidance) -> OFFER: disclose with prescribing context Finding 4 (polygenic risk score without ancestry validation) -> REVIEW: return only with ancestry-validated performance and support ``` Individual research teams often lack the expertise to evaluate every finding themselves. The SickKids Genome Board shows the alternative, a no-cost centralized consultation service that triages clinical questions arising from genomic research, with submission volumes rising year over year [8]. Researchers themselves are key stakeholders in these decisions. In-depth interviews with 16 researchers across 11 sites and 6 research roles in the MoTrPAC multi-omics consortium found generally positive attitudes toward hypothetical return of multi-omics results, with respondents citing the potential value of medically relevant findings [4]. ### Step 4. Confirm Research-Grade Findings in a Clinical Laboratory Research sequencing is not clinical testing. A variant called pathogenic in a research pipeline may not meet the analytical standards of a certified clinical laboratory, and reports from research assays typically carry the exact message "for research use only, not for clinical decision making." The fix is confirmation before disclosure. The SickKids Genome Board explicitly recommended clinical confirmation with genetic counseling as the route for variants judged returnable [8]. Budget for this step at proposal time, because it is the bridge between a research observation and a result a participant can take to a clinician. ### Step 5. Disclose With Counseling and Support Disclosure is a process, not an envelope. The evidence points to four design requirements. Counseling reduces uncertainty. A systematic review of 45 studies of whole genome and whole [exome sequencing](/blog/guides/exome-sequencing) in adults found that feelings of uncertainty were less present among individuals who received genetic counseling, and that negative experiences, while frequently reported, were typically of low intensity [12]. Tailor support to the condition. In the 100,000 Genomes Project evaluation of additional findings, 82 percent of participants who received a positive additional finding said the result was useful and would influence their health management, and 90 percent shared it with family members. Experiences differed by condition. Participants with cancer susceptibility results were often initially shocked and anxious and found telling family challenging, while participants with familial hypercholesterolemia results had an easier path. Participants who received no additional findings mostly had positive experiences, but some held misunderstandings, and the study authors called for greater support for this group [2]. Use technology to scale without losing quality. Interactive web-based tools can educate participants, deliver results directly, and facilitate family sharing, and a randomized trial of one such tool in cancer patients is testing whether this approach improves recall of results and receipt of guideline concordant care [13]. Even unconventional data types can be returned well with the right translation. A dietary genomics pilot translated stool [DNA sequencing](/blog/guides/dna-sequencing) into a personal food profile report, and the report alone, with no monetary compensation, achieved a 72.1 percent sample return rate, with 81.2 percent of surveyed participants finding the report easy to understand [14]. ### Step 6. Stand Up an Urgent and Emergent Pathway Some research procedures generate findings that cannot wait for a scheduled disclosure visit. The Project Baseline Health Study, a prospective observational cohort of 2,502 participants, built a systematic process for urgent or emergent results from vital signs, clinical laboratory testing, and ocular, cardiovascular, and pulmonary imaging. Among 2,002 participants analyzed, 39.7 percent had at least one urgent or emergent finding returned, representing 1,159 results over three years. The most common were eye findings, 246, pulmonary nodules, 159, abnormal stress echocardiograms, 123, bradycardia on resting electrocardiograms, 74, and lung parenchyma findings, 55 [15]. Worked calculation: 2,002 x 0.397 = 794.8, so about 795 participants needed urgent communication, and 1,159 / 795 = 1.46 results per affected participant. If your study includes imaging or clinical laboratory testing, plan staffing for a pathway like this rather than treating urgent findings as rare exceptions. ### Step 7. Set a Raw Data Policy Participants increasingly ask for their raw genomic data, and the legal position varies by jurisdiction. In an Australian interview study spanning two [whole genome sequencing](/blog/guides/whole-genome-sequencing) research programs, stakeholders including health professionals, scientists, bioinformaticians, patients, and patient advocates overwhelmingly supported returning raw data on request, grounded in ethical imperatives. The same stakeholders stressed that return must come with support, including explanation and, where necessary, counseling and clinical advice, and that adequate resourcing must be built into projects from the outset given rising demand [3]. A consultation service can expect these requests as a routine submission category, which is exactly what the SickKids Genome Board observed [8]. ### Step 8. Evaluate, Document, and Report Back Close the loop three ways. First, evaluate your disclosure process against outcomes such as comprehension, recall, and trust, the same outcomes the report-back literature uses [7]. Second, document every triage decision so your ethics committee can audit the pathway, and check the pathway is working by reviewing a sample of decisions against your written criteria on a regular schedule. Third, return aggregate results to the whole cohort, since community engagement work in brain tumor genomics found that participants view aggregate results as part of the reciprocity they expect, alongside individual results [5]. ### Practical Tips for First-Time Implementers - Budget return of results as core infrastructure at proposal stage, not as an afterthought. - Expect only about half of expert-reviewed variants to qualify for return, and staff accordingly [8]. - Put a named genetics professional or consultation service in your protocol before enrollment opens [8]. - Plan support for participants who receive no findings, since misunderstanding happens in that group too [2]. - Decide your raw data policy before the first request arrives [3]. ## Decision Table for Common Result Types | Result type | Example from practice | Typical decision | Support required | |--|--|--|--| | Urgent clinical finding | Lung nodule or abnormal cardiac imaging during research visits | Contact promptly, activate referral | Documented contact plan, clinical referral pathway [15] | | Pathogenic variant, preventable or treatable condition | Cancer susceptibility or familial hypercholesterolemia variant | Confirm clinically, then offer with counseling | Clinical confirmation, genetic counseling [2] [8] | | Pharmacogenomic variant | Variant affecting drug response | Offer with prescribing context | Prescribing guidance, clinician handoff [1] | | Polygenic risk score | Multi-variant risk estimate for a common disease | Return only with validated performance and careful framing | Ancestry-specific validation, counseling [1] [9] | | Carrier status | Recessive carrier trait found during screening | Offer per consent and counseling plan | Reproductive counseling context [16] | | Raw genomic data | Whole genome sequence file | Return on request | Explanation, counseling, clinical advice [3] | | Aggregate results | Cohort-level findings | Report back to all participants | Plain-language summary [5] [7] | ## Adolescents and Young Adults: Deciding With, Not For ![Decision path for whether to offer genomic results to a young person, from assent at 13 to 17 through consent at 18 to 21.](/article-images/illustrations/return-of-individual-research-results-genomic-studies-adolescent-results.webp) Professional organizations historically discouraged returning predictive adult-onset results and carrier status to children to protect their future autonomy. Recent clinical guidance has diverged from that norm, suggesting that when minors undergo genomic sequencing, parents and children should have the opportunity to learn secondary findings, including for some adult-onset conditions, and the American Society of Human Genetics Workgroup on Pediatric Genetic and Genomic Testing has suggested including adolescents in the decision-making process [16]. The evidence base for including young people is growing. A clinical trial enrolled 483 adolescents and young adults, ages 13 to 21, who used an online tool to decide whether to learn personal results for 32 sets of treatable, preventable, and adult-onset conditions and carrier traits, with assent, meaning the agreement of a minor who cannot legally consent, for ages 13 to 17 and full consent for ages 18 to 21 [16] [17]. In follow-up interviews with 11 participants ages 14 to 19 who received pathogenic or likely pathogenic results, most accurately recalled their results and reported satisfaction with learning the information despite short-lived anxiety and confusion. Most viewed their results as a future consideration, and several participants' family members underwent cascade testing, meaning relatives were tested for the family variant after the young person's result [17]. ## Equity, Community Engagement, and Trust Return of results is not equity neutral. A National Heart, Lung and Blood Institute workshop on return of secondary findings named health equity and community engagement as structural prerequisites for ethical practice, not optional add-ons [1]. The reasons are concrete. Focus groups with 23 participants self-identifying as American Indian or Alaska Native, African American or Black, or Hispanic or Latino in a Colorado biobank found that motivations for participation included the potential for return of results and the desire to help the biobank represent all populations, meaning return of results is itself an engagement tool for underrepresented communities [18]. African genomics stakeholders surveyed about feedback of individual findings endorsed returning clinically actionable results but called for precise guidance on how to do it in their research contexts [6]. Communication design determines whether equity goals are met. In a real-world evaluation of 1,690 patients offered genomic testing for rare diseases and cancer, 90 percent accepted testing, but patients who spoke English as an additional language were less likely to report receiving enough information at pre-test counseling, 88 percent versus 96 percent, and 10 percent of respondents who received results had moderate to high decision regret, predicted by English as an additional language and insufficient information at consent [19]. Engagement discussions also reveal a gap between what communities expect and what research practice delivers, including misconceptions about the clinical applicability of research findings, which makes pre-study dialogue essential [5]. ## What Real-World Outcomes Look Like Among 1,147 people who completed a post-result questionnaire after elective genomic sequencing across academic, clinical, and commercial providers, 60.3 percent self-reported receiving results they assessed as important, 75.9 percent reported a form of health-related utility, and 74.1 percent discussed results with family, while only 41.7 percent discussed them with a healthcare provider outside the study team and 23.1 percent had a medical visit as a direct result [20]. That gap between family sharing and clinical follow-up is a design signal, since participants need help connecting results to care. Disease context changes the calculus. In Parkinson disease, returning results to diagnosed patients can provide insight and access to targeted therapy trials but requires careful framing to avoid overinterpretation, while predictive testing in at-risk but undiagnosed individuals offers limited clinical utility and can introduce psychological, familial, and insurance implications, and current practice remains inconsistent with major gaps in counseling access [9]. ## Common Mistakes and Limitations 1. **Treating consent as a one-time signature.** Participants hold misconceptions about what research results mean clinically and how specimens are used [5]. Consent should be a communication plan with named result categories, and structured tools such as question prompt lists improve the quality of decisions [11]. 2. **Assuming every finding is returnable.** Triage exists precisely because only a subset of findings passes the actionability, validity, and reliability filter. Build the triage step before enrollment, not after results exist. 3. **Disclosing unconfirmed research-grade variants.** A research call of pathogenic is not a clinical diagnosis. Confirm in a clinical laboratory before disclosure [8]. 4. **Ignoring urgent incidental findings.** Research imaging and laboratory testing surface time-critical findings at meaningful rates, and without a pathway they surface late or never [15]. 5. **Neglecting the no-finding group.** Participants who receive no results can still misunderstand what was looked for and what was not [2]. Write a no-result letter that explains the scope of the search. 6. **Assuming broad consent covers every future use.** Willingness to share varies sharply by organization type, so capture preferences explicitly instead of assuming one consent line covers every scenario [10]. 7. **Returning probabilistic results without framing.** Polygenic and other risk estimates need ancestry-validated performance and counseling support, or participants will overinterpret them [1] [9]. 8. **Skipping community engagement.** Return of results is a structural equity prerequisite, and underrepresented communities cite return as a participation motivation [1] [18]. 9. **Discovering the costs after the fact.** Confirmation testing, counseling time, and disclosure logistics must be resourced from the outset [3]. 10. **Limitation.** Evidence and guidance are still developing, standardized guidelines remain limited [7], and any individual case, whether a specific variant or a specific participant's situation, needs a genetics professional rather than a general workflow. ## Frequently Asked Questions ### What are individual research results in genomic studies? Individual research results are findings generated from one participant's own genome or samples during a study, as opposed to aggregate results that summarize the whole cohort. They include primary findings related to the study question, secondary or incidental findings unrelated to the study aim, and sometimes raw genomic data. ### Which results should researchers return to participants? Return results that are clinically actionable, analytically valid, and reliable, especially when a preventable or treatable action exists. Most frameworks also support returning urgent clinical findings and aggregate study results, while exploratory findings such as unvalidated risk scores stay out of individual disclosure. ### Are researchers required to return secondary or incidental findings? There is no single global rule, since obligations vary by jurisdiction, study design, and consent language. The practical standard in large cohort programs is to decide in advance which secondary finding categories you will offer, name them in the consent process, and confirm any research-grade result in a clinical laboratory before disclosure. ### What is the difference between a research result and a clinical result? A research result comes from an assay that may not meet clinical laboratory standards, so it cannot support medical decisions on its own. A clinical result comes from a certified clinical laboratory with validated methods. Research findings that look returnable should be confirmed clinically before participants act on them. ### How should researchers handle requests for raw genomic data? Treat raw data requests as an expected part of study operations rather than an exception. Stakeholders across research and clinical roles broadly support returning raw data on request, provided participants receive explanation and, where needed, counseling or clinical advice, with that support budgeted from the start. ### Should adolescents receive genomic research results? Adolescents should increasingly be included in decisions about their own genomic results rather than having parents decide alone. Early evidence shows young people can make these decisions thoughtfully and generally cope well with results when counseled, so structured assent and age-appropriate counseling are the key requirements. ### What support do participants need after receiving a positive result? Participants need genetic counseling, a clear explanation of what the result does and does not mean, a clinical referral pathway, and help with family communication. Support should be tailored to the condition, since results tied to cancer risk tend to cause more initial distress than results for treatable metabolic conditions. ### How should a study budget for return of results? Budget at the proposal stage for confirmation testing, genetic counseling staff time, disclosure platform or personnel costs, participant contact logistics, and aggregate report preparation. Programs that treat return of results as core infrastructure avoid discovering these costs after results already exist. ## Sources 1. [Recommendations for return of secondary genomic findings in observational cohort studies.](https://pubmed.ncbi.nlm.nih.gov/42728385/) 2. [Evaluating the return of additional findings from the 100,000 Genomes Project: A mixed-methods study exploring participant experiences of receiving secondary findings from genomic sequencing.](https://pubmed.ncbi.nlm.nih.gov/40260669/) 3. [Regulatory Guidance for the Return of Raw Genomic Data to Research Participants: A Qualitative Interview Study.](https://pubmed.ncbi.nlm.nih.gov/42237911/) 4. [Researcher views on returning results from multi-omics data to research participants: insights from The Molecular Transducers of Physical Activity Consortium (MoTrPAC) Study.](https://pubmed.ncbi.nlm.nih.gov/39920727/) 5. [Community perspectives on the return of research results and ownership of data and specimens for brain tumor genomic research.](https://pubmed.ncbi.nlm.nih.gov/42389225/) 6. [Perspectives of researchers, science policy makers and research ethics committee members on the feedback of individual genetic research findings in African genomics research.](https://pubmed.ncbi.nlm.nih.gov/38849807/) 7. [Strategies to facilitate the report-back of research results: a systematic review of methods and evaluations.](https://pubmed.ncbi.nlm.nih.gov/41772658/) 8. [Implementing a consultation service for translating genomic research findings into the clinic: Lessons from the SickKids Genome Board.](https://pubmed.ncbi.nlm.nih.gov/41049695/) 9. [Return of genetic results to persons with Parkinson's disease: Blessing or foe?](https://pubmed.ncbi.nlm.nih.gov/42474300/) 10. [Individuals' preferences for future biological sample and genomic data sharing in the Australian Reproductive Genetic Carrier Screening Project.](https://pubmed.ncbi.nlm.nih.gov/41741683/) 11. [Development of a question prompt list to support Consent for Genomic Testing (CoGenT) and research.](https://pubmed.ncbi.nlm.nih.gov/42168721/) 12. [The Psychosocial Impact of Receiving Whole Genome and Whole Exome Sequencing Results in Adults: A Systematic Review.](https://pubmed.ncbi.nlm.nih.gov/42781942/) 13. [Rationale and study design for a randomized clinical trial of HOPE-Genomics, a web-based intervention to improve cancer patients' understanding of genomic testing results.](https://pubmed.ncbi.nlm.nih.gov/42217668/) 14. [Returning Genomic Dietary Data to Participants by Translating Stool DNA into a Personal Food Profile.](https://pubmed.ncbi.nlm.nih.gov/42619982/) 15. [Returning Individual-Level Urgent or Emergent Research Results to Participants: The Project Baseline Health Study Experience.](https://pubmed.ncbi.nlm.nih.gov/40166487/) 16. [Engaging adolescents and young adults in decisions about return of genomic research results: study protocol for a mixed-methods longitudinal clinical trial protocol.](https://pubmed.ncbi.nlm.nih.gov/39696322/) 17. [Adolescent and Young Adult Perspectives on Receiving Pathogenic or Likely Pathogenic Results in a Prospective Genomic Screening Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/42263029/) 18. [Underrepresented voices in a Colorado Biobank: Perspectives from focus groups on motivations, return of results, and data sharing.](https://pubmed.ncbi.nlm.nih.gov/42613837/) 19. [Patients offered genomic testing for rare disease and cancer: a real-world evaluation of impact and processes of care.](https://pubmed.ncbi.nlm.nih.gov/42156518/) 20. [Elective genomic sequencing for adults in research, clinical and commercial contexts.](https://pubmed.ncbi.nlm.nih.gov/42400015/)